The vaccine candidate, NVX‑CoV2373, was tested in healthy adults between the ages of 18 and 59. The participants tolerated the vaccine well, as only expected adverse reactions, such as tenderness and fatigue, were reported.
The vaccine candidate caused all participants to develop anti-spike IgG antibodies after their first injection, with some developing wild-type virus neutralizing antibodies as well. After the second dosage, all participants had developed both types of antibodies.
“The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well-tolerated COVID-19 vaccine with a robust immunogenicity profile,” Gregory Glenn, MD, Novavax’s president of research and development, said in an Aug. 4 news release. “Using a stringent wild-type virus assay performed by investigators at the University of Maryland School of Medicine, NVX-CoV2373 elicited neutralizing antibody titers greater than those observed in a pool of COVID-19 patients with clinically significant disease.”
More articles on pharmacy:
3 retail pharma giants disclose data breaches from break-ins: What to know
Amazon’s PillPack partners with New Jersey insurer, Prime Therapeutics
American women more likely than men to skip medication due to cost, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
